Pirjo Nykänen

Predicting the effect of prandial stage and particle size on absorption of ODM-204.

A. Juppo, T. Korjamo, R. Schilderink, 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

K. Fizazi, C. Massard, P. Bono, 2017, European urology focus.

ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer.

K. Fizazi, C. Massard, P. Bono, 2017 .

Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans

M. Kähkönen, M. Koskinen, T. Korjamo, 2021, Drug Metabolism and Disposition.

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

T. Tammela, A. Snapir, K. Fizazi, 2016, European urology.

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

J. Palvimo, R. Riikonen, G. Wohlfahrt, 2015, Scientific Reports.

Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

T. Tammela, K. Fizazi, C. Massard, 2015 .

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).

T. Tammela, A. Snapir, K. Fizazi, 2014 .

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

M. Koskinen, F. Huang, Pirjo Nykänen, 2021, Clinical Pharmacokinetics.

Discovery of ODM-201, a new- generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer

J. Palvimo, R. Riikonen, G. Wohlfahrt, 2015 .

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

J. Palvimo, R. Riikonen, A. Moilanen, 2015, Scientific Reports.